Kronos Bio Inc. (KRON): Price and Financial Metrics
KRON Price/Volume Stats
| Current price | $0.96 | 52-week high | $1.60 |
| Prev. close | $0.93 | 52-week low | $0.69 |
| Day low | $0.92 | Volume | 78,700 |
| Day high | $0.97 | Avg. volume | 278,921 |
| 50-day MA | $0.94 | Dividend yield | N/A |
| 200-day MA | $1.04 | Market Cap | 57.80M |
KRON Stock Price Chart Interactive Chart >
Kronos Bio Inc. (KRON) Company Bio
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
KRON Price Returns
| 1-mo | 9.80% |
| 3-mo | -6.80% |
| 6-mo | -4.95% |
| 1-year | -25.00% |
| 3-year | -93.73% |
| 5-year | N/A |
| YTD | -23.20% |
| 2023 | -22.84% |
| 2022 | -88.08% |
| 2021 | -54.50% |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...